NewsBenzingaBTIG bekräftigt Kaufempfehlung für ArriVent BioPharma und bestätigt Kursziel von 29 $ BTIG bekräftigt Kaufempfehlung für ArriVent BioPharma und bestätigt Kursziel von 29 $ Benzinga 2026.10.16 18:21 (GMT+0) Open on Benzinga Other news Barclays Maintains Equal-Weight on Exelon, Lowers Price Target to $44 The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition. Citizens Financial Analysts Slash Their Forecasts Following Q3 Results Barclays Maintains Overweight on Evergy, Lowers Price Target to $86 Mastercard Brings Its Fraud-Fighting Tools to Stablecoin Payments Barclays Maintains Overweight on Entergy, Lowers Price Target to $115
The FTC Allows Publicis’ LiveRamp Acquisition To Move Forward With Safeguards To Protect Customer Data And Fair Competition.
